T. Rowe Price Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2023
Q4
Sell
-11,678
Closed -$131K 2909
2023
Q3
$131K Buy
+11,678
New +$131K ﹤0.01% 2604
2023
Q2
Sell
-162,694
Closed -$6.58M 2900
2023
Q1
$6.58M Sell
162,694
-11,609
-7% -$470K ﹤0.01% 1124
2022
Q4
$8.11M Sell
174,303
-66,384
-28% -$3.09M ﹤0.01% 1091
2022
Q3
$12.5M Buy
240,687
+52,344
+28% +$2.72M ﹤0.01% 1022
2022
Q2
$8.9M Sell
188,343
-4,716
-2% -$223K ﹤0.01% 1336
2022
Q1
$13.7M Sell
193,059
-81,258
-30% -$5.78M ﹤0.01% 1318
2021
Q4
$20.5M Buy
274,317
+12,194
+5% +$912K ﹤0.01% 1282
2021
Q3
$14.9M Buy
262,123
+9,341
+4% +$531K ﹤0.01% 1365
2021
Q2
$11.1M Sell
252,782
-611,479
-71% -$26.9M ﹤0.01% 1401
2021
Q1
$42.6M Sell
864,261
-97,184
-10% -$4.79M ﹤0.01% 1052
2020
Q4
$40.5M Sell
961,445
-12,984
-1% -$547K ﹤0.01% 1031
2020
Q3
$44.6M Sell
974,429
-308,128
-24% -$14.1M 0.01% 910
2020
Q2
$64.4M Sell
1,282,557
-72,381
-5% -$3.63M 0.01% 765
2020
Q1
$69.7M Sell
1,354,938
-41,397
-3% -$2.13M 0.01% 685
2019
Q4
$86.3M Sell
1,396,335
-158,917
-10% -$9.82M 0.01% 713
2019
Q3
$93.4M Buy
1,555,252
+26,711
+2% +$1.6M 0.01% 646
2019
Q2
$129M Buy
1,528,541
+159,504
+12% +$13.5M 0.02% 581
2019
Q1
$131M Buy
1,369,037
+295,615
+28% +$28.2M 0.02% 567
2018
Q4
$76M Buy
1,073,422
+10,338
+1% +$732K 0.01% 679
2018
Q3
$90.9M Buy
1,063,084
+207,593
+24% +$17.7M 0.01% 701
2018
Q2
$99.2M Buy
855,491
+537,087
+169% +$62.2M 0.02% 660
2018
Q1
$25.8M Sell
318,404
-53,606
-14% -$4.34M ﹤0.01% 1094
2017
Q4
$21.8M Buy
372,010
+269,566
+263% +$15.8M ﹤0.01% 1148
2017
Q3
$4.79M Buy
+102,444
New +$4.79M ﹤0.01% 1427